Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

BACKGROUND: Over the past years, EGFR tyrosine kinase inhibitors (TKI) revolutionized treatment response. 1st-generation (reversible) EGFR TKI and later the 2nd –generation irreversible EGFR TKI Afatinib were aimed to improve treatment response. Nevertheless, diverse resistance mechanisms develop wi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Wagener-Ryczek, Svenja, Heydt, Carina, Süptitz, Juliane, Michels, Sebastian, Falk, Markus, Alidousty, Christina, Fassunke, Jana, Ihle, Michaela Angelika, Tiemann, Markus, Heukamp, Lukas, Wolf, Jürgen, Büttner, Reinhard, Merkelbach-Bruse, Sabine
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7216404/
https://ncbi.nlm.nih.gov/pubmed/32397977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06920-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars